Exhibit 10.3 AMENDED AND RESTATED SEVERANCE AGREEMENT AND RELEASE This AMENDED AND RESTATED AGREEMENT (the "Agreement") is made by and between Curis, Inc. (the "Company") and Dr. Doros Platika (the "Executive"). All capitalized words and terms used in...Severance Agreement • November 12th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
LEASELease Agreement • March 14th, 2000 • Curis Inc
Exhibit 10.56 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED...Warrant Agreement • March 14th, 2000 • Curis Inc • California
COMMON STOCK PURCHASE WARRANT CURIS, INC.Common Stock Purchase Warrant • October 30th, 2024 • Curis Inc • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on October 30, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Curis, Inc., a Delaware corporation (the “Company”), up to [_________] shares (as subject to adjustment hereunder, the “Warrant Shares”) of common stock, par value $0.01 per share, of the Company (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 11th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 11, 2020, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 2.1 ----------- CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. AGREEMENT FOR PURCHASE AND SALE OF SINGLE-CHAIN POLYPEPTIDE BUSINESS This Purchase Agreement and Sale...Purchase and Sale Agreement • July 2nd, 2001 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
SECTION 1 AMOUNT AND TERMS OF CREDIT AND INTEREST THE TERM LOANLoan Agreement • June 17th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.48 REGISTRATION RIGHTS AGREEMENT This Agreement dated as of July 1, 1996 is entered into by and among Biogen, Inc., a Massachusetts corporation (the "Purchaser") and Ontogeny, Inc., a Delaware corporation (the "Company"). WHEREAS, the...Registration Rights Agreement • April 3rd, 2000 • Curis Inc • Massachusetts
AMENDED AND RESTATED LICENSE AGREEMENT (EXCLUSIVE)License Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.48 ------------- PURCHASE AGREEMENT THIS AGREEMENT is made as of the __ day of November, 2000, by and among Curis, Inc. (the "Company"), a corporation organized under the laws of the State of Delaware, with its principal offices at 61...Purchase Agreement • November 29th, 2000 • Curis Inc • Biological products, (no disgnostic substances) • New York
CURIS, INC. 25,652,174 Shares of Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • December 10th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • New York
Curis, Inc., a Delaware corporation (the “Company”), proposes to issue and sell, pursuant to the terms of this Underwriting Agreement (the “Agreement”) to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 25,652,174 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”). The 25,652,174 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 3,847,826 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of July 18, 2001, among Curis, Inc., a Delaware corporation (the "Company"), Elan International Services, Ltd., a Bermuda exempted limited liability...Securities Purchase Agreement • August 14th, 2001 • Curis Inc • Biological products, (no disgnostic substances) • New York
CURIS, INC.Registration Rights Agreement • August 14th, 2001 • Curis Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.32 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AGREEMENT MICHIGAN FILE [**], [**], [**] & [**] TECHNOLOGY This Agreement is effective as of the 30th...License Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances)
LEASE between ------------- MOULTON REALTY COMPANY ---------------------- and --- ONTOGENY, INC. --------------Lease Agreement • March 14th, 2000 • Curis Inc • Delaware
Exhibit 10.4 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement"), made as of the 1/st/ day of August, 2002, is entered into by and between Curis, Inc., a Delaware corporation (the "Company"), and Christopher U. Missling (the "Employee")....Employment Agreement • November 12th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
LETTER OF INTENTLetter of Intent • July 2nd, 2001 • Curis Inc • Biological products, (no disgnostic substances)
The Parties intend to enter into two further agreements, a Target Research and License Agreement and a Development Agreement, within the next two weeks (extendible by mutual agreement). Under the Development Agreement, the Parties will jointly develop therapeutic antibody(ies). The agreement may provide either party the option to withdraw from the project at certain agreed time points. In that case, the other party may develop the antibody on its own or with a partner, and the Parties agree that, to the extent possible, all Curis or Micromet Patent Rights relevant to the Therapeutic Antibody will be licensed or sublicensed to the Party continuing development, to the extent necessary for such continued development.
CURIS, INC. SALES AGREEMENTSales Agreement • July 2nd, 2015 • Curis Inc • Biological products, (no disgnostic substances) • New York
AgreementCollaboration Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
AMONGMerger Agreement • March 14th, 2000 • Curis Inc • Delaware
Exhibit 10.65 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT Effective as of November 2, 1998 ("Effective Date"), THE BOARD OF TRUSTEES OF THE...Exclusive License Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • California
EXCLUSIVE)Patent License Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.45 FIRST AMENDMENT TO SECURED PROMISSORY NOTE This First Amendment to Secured Promissory Note dated August 3, 2001 in the original principal amount of $500,000 executed by Doros Platika (the "Obligor") on behalf of Curis, Inc. (the...Secured Promissory Note • March 29th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.54 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED...Warrant Agreement • March 14th, 2000 • Curis Inc • California
b) The Company shall tend to the Employee $100,000, which shall be due and payable on June 30, 1997. Such loan shall bear interest at the minimum applicable federal interest rate for loans of such duration. Such loan shall be secured by a mortgage on...Employment Agreement • March 30th, 2001 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 10.02 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. Amendment to License Agreement Effective as of September 1, 2000 Re: Harvard Cases 956; 963 President and...License Agreement • November 14th, 2000 • Curis Inc • Biological products, (no disgnostic substances)
or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing...Securities Purchase Agreement • July 6th, 2023 • Curis Inc • Biological products, (no disgnostic substances) • New York
March 12, 2002 Dr. Doros Platika Curis, Inc. 61 Moulton Street Cambridge, MA 02138 Dear Doros: Reference is made to our letter agreement dated January 28, 2002 (the "January Letter Agreement"), relating to your severance arrangements and ongoing...Severance Agreement • March 29th, 2002 • Curis Inc • Biological products, (no disgnostic substances)
Reference is made to our letter agreement dated January 28, 2002 (the "January Letter Agreement"), relating to your severance arrangements and ongoing relationship with Curis, Inc. (the "Company"). This letter agreement will confirm that, notwithstanding the provisions of the second sentence of section 1 of the January Letter Agreement, you may actively pursue other employment opportunities, including self employment opportunities, as of the date of this letter agreement. All other provisions of your January Letter Agreement remain in full force and effect, and you specifically acknowledge your continued obligations under section 6 of the January Letter Agreement relating to your Invention and Non-Disclosure Agreement and Non-Compete and Non-Solicitation Agreement (as defined therein).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • February 27th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • Illinois
COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of February 26, 2020 by and between CURIS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 30th, 2024 • Curis Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 28, 2024, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 10.01 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this "Amendment") is executed by and between David E. Clem and David M. Roby, Trustees (the "Landlord") of 21 Erie Realty Trust u/d/t dated May 16, 1996, recorded with the...Lease • August 14th, 2000 • Curis Inc • Biological products, (no disgnostic substances)
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 27th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 26, 2020, by and between CURIS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
6,449,288 Shares Warrants to Purchase 1,612,322 Shares CURIS, INC. Common Stock PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • January 22nd, 2010 • Curis Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.2 LEASE TERMINATION AGREEMENT This Lease Termination Agreement (this "Agreement") is executed by and between David E. Clem and David M. Roby, Trustees (the "Landlord") of 21 Erie Realty Trust u/d/t dated May 16, 1996, recorded with the...Lease Termination Agreement • November 12th, 2002 • Curis Inc • Biological products, (no disgnostic substances)
Exhibit 10.49 REGISTRATION RIGHTS AGREEMENT This Agreement dated as of September 26, 1996 is entered into by and among Corange International Limited, (the "Purchaser") and Ontogeny, Inc., a Delaware corporation (the "Company"). WHEREAS, the Company...Registration Rights Agreement • April 3rd, 2000 • Curis Inc • Massachusetts
